Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.

Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, Mercola D, McGuire KL.

Int J Cancer. 2014 Jan 1;134(1):81-91. doi: 10.1002/ijc.28326. Epub 2013 Jul 13.


African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.

Kryvenko ON, Balise R, Soodana Prakash N, Epstein JI.

J Urol. 2016 Feb;195(2):301-6. doi: 10.1016/j.juro.2015.08.089. Epub 2015 Sep 2.


Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients.

Guo Y, Sigman DB, Borkowski A, Kyprianou N.

Prostate. 2000 Feb 1;42(2):130-6.


Tumor immunobiological differences in prostate cancer between African-American and European-American men.

Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S.

Cancer Res. 2008 Feb 1;68(3):927-36. doi: 10.1158/0008-5472.CAN-07-2608.


A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?

Schreiber D, Chhabra A, Rineer J, Weedon J, Schwartz D.

Clin Genitourin Cancer. 2015 Aug;13(4):e259-64. doi: 10.1016/j.clgc.2015.02.006. Epub 2015 Feb 21.


Genes associated with prostate cancer are differentially expressed in African American and European American men.

Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, Herawi M, Everson R, Giroux CN, Schwartz AG, Bollig-Fischer A.

Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):891-7. doi: 10.1158/1055-9965.EPI-12-1238. Epub 2013 Mar 20.


Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.

Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR.

Eur Urol. 2015 Mar;67(3):451-7. doi: 10.1016/j.eururo.2014.03.026. Epub 2014 Apr 5.


Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.

Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascón P, Mellado B.

Mol Cancer Ther. 2014 May;13(5):1270-84. doi: 10.1158/1535-7163.MCT-13-0775. Epub 2014 Mar 21.


Genetic ancestry, self-reported race and ethnicity in African Americans and European Americans in the PCaP cohort.

Sucheston LE, Bensen JT, Xu Z, Singh PK, Preus L, Mohler JL, Su LJ, Fontham ET, Ruiz B, Smith GJ, Taylor JA.

PLoS One. 2012;7(3):e30950. doi: 10.1371/journal.pone.0030950. Epub 2012 Mar 27.


Clinical profile, quality of care, and recurrence in Arab-American and Caucasians prostate cancer patients in Michigan.

Moussawi AH, Yassine M, Dey S, Soliman AS.

J Immigr Minor Health. 2013 Aug;15(4):803-9. doi: 10.1007/s10903-012-9662-y.


Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with caucasian prostate cancer patients.

Caruso RP, Levinson B, Melamed J, Wieczorek R, Taneja S, Polsky D, Chang C, Zeleniuch-Jacquotte A, Salnikow K, Yee H, Costa M, Osman I.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):222-7.


Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China.

Zhu J, Pan C, Jiang J, Deng M, Gao H, Men B, McClelland M, Mercola D, Zhong WD, Jia Z.

Oncotarget. 2015 Jun 30;6(18):16757-65.


TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M.

Prostate. 2011 Apr;71(5):489-97. doi: 10.1002/pros.21265. Epub 2010 Sep 28.


Copy number and gene expression differences between African American and Caucasian American prostate cancer.

Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, Yu JZ, Dash A, Jean-Gilles J, Reuter V, Gerald WL, Lee P, Osman I.

J Transl Med. 2010 Jul 22;8:70. doi: 10.1186/1479-5876-8-70.


Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.

Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, Rayford W.

Prostate Cancer Prostatic Dis. 2008;11(3):274-9. doi: 10.1038/pcan.2008.5. Epub 2008 Feb 12.


Cell line modeling to study biomarker panel in prostate cancer.

NickKholgh B, Fang X, Winters SM, Raina A, Pandya KS, Gyabaah K, Fino N, Balaji KC.

Prostate. 2016 Feb 15;76(3):245-58. doi: 10.1002/pros.23116. Epub 2015 Nov 2.


Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.

Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E.

J Natl Cancer Inst. 2000 Dec 20;92(24):2009-17.


Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP.

Steck SE, Arab L, Zhang H, Bensen JT, Fontham ET, Johnson CS, Mohler JL, Smith GJ, Su JL, Trump DL, Woloszynska-Read A.

PLoS One. 2015 Apr 28;10(4):e0125151. doi: 10.1371/journal.pone.0125151. eCollection 2015.


Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.

Leach DA, Need EF, Toivanen R, Trotta AP, Palethorpe HM, Tamblyn DJ, Kopsaftis T, England GM, Smith E, Drew PA, Pinnock CB, Lee P, Holst J, Risbridger GP, Chopra S, DeFranco DB, Taylor RA, Buchanan G.

Oncotarget. 2015 Jun 30;6(18):16135-50. Erratum in: Oncotarget. 2015 Nov 3;6(34):36923. Palenthorpe, Helen M [Corrected to Palethorpe, Helen M].

Supplemental Content

Support Center